Navigation Links
Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting

REDWOOD CITY, Calif., April 29, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society (ATS). PT003 (GFF-MDI) is a proprietary, fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, an established, long-acting beta-2 agonist (LABA) delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA MDI).  It is the first and only dual long-acting rapid bronchodilator LAMA-LABA combination product in development in an HFA MDI formulation, the most widely used inhalation drug delivery format.

"Our presentation at this year's ATS represents a particularly important step in the progression of Pearl's bronchodilator franchise," said Chuck Bramlage, Pearl Therapeutics' chief executive officer. "Not only is it an opportunity to present our strong clinical evidence to peers, but from a business perspective, it speaks to the speed and fiscal efficiency with which Pearl has expedited the clinical development of our lead bronchodilator combination and its individual components. In fewer than four years since initial financing, Pearl has completed the significant Phase 2b study being highlighted at ATS, as well as other key clinical and non-clinical studies. This is a testimonial to the Pearl team and its novel co-suspension platform.  We expect this momentum will continue as we advance PT003 and its components, into a series of four additional Phase 2b studies, and make plans for Phase 3 trials in parallel."

The ATS annual meeting is taking place May 13-18 in the Colorado Convention Center in Denver, CO. Information regarding the ATS presentations is below and full abstracts will be available through the American Journal of Respiratory and Critical Care Medicine journal website beginning on May 2 at Date/Time: Wednesday, May 18, 2011 from 8:15am – 10:45amPoster Title: Pearl Therapeutics' combination LAMA/LABA MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a Randomized, Double-Blind, Placebo-Controlled Phase 2b StudyAbstract Number: 611 Session and Location: D30 , Room 403-404, Colorado Convention CenterIn December 2010, Pearl released top-line Phase 2b results   from this study, which demonstrated that PT003 provides superior bronchodilation compared to the current market leader, Spiriva, as well as to Foradil, placebo and PT003's individual components, Pearl's glycopyrrolate MDI (PT001; GP MDI) and formoterol MDI (PT005; FF MDI). The p-value for all comparisons was <0.0002. Additional data on primary and secondary endpoints will be presented at ATS.  

Phase 2b Study DesignThis Phase 2b study randomized 118 patients to one of the following study arms: high or low dose PT003 administered twice-daily (BID), high or low dose PT001, PT005, tiotropium bromide (Spiriva® Handihaler®), formoterol fumarate (Foradil® Aerolizer®) and placebo. Placebo, PT003, PT001 and PT005 were administered BID via HFA MDI for one week while Spiriva and Foradil were administered according to their approved label: 18 ug once daily (via Handihaler® inhaler) and 12 ug BID (via Aerolizer® inhaler), respectively, each for one week. The primary endpoint in this study was an improvement in lung function as assessed by FEV1 AUC0-12 (forced expiratory volume in one second)*, relative to baseline at the start of treatment.  

About COPDChronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment. Pearl is developing inhaled combination products designed to optimize the treatment of COPD.

About Pearl Therapeutics Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003 (GFF-MDI), an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010 (GMFF MDI), a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle co-suspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit

* FEV1 (forced expiratory volumes in one second) is a common measurement of lung function in patients with asthma, cystic fibrosis, and COPD and is typically used to predict the severity of pulmonary disease. AUC (area under the curve) is a measure of therapeutic benefit over a period of time.

Editor's note: Spiriva® HandiHaler® (tiotropium bromide inhalation powder) is a registered trademark of Boehringer Ingelheim Pharmaceuticals; Foradil® is a registered trademark of Astellas Pharma; and Aerolizer® is a registered trademark of Novartis AG.


SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
3. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
5. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
6. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
7. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
8. New Biopharmaceutical Company to Accelerate Delivery of Vaccines and Protein Therapeutics
9. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
10. Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
11. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Post Your Comments:
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa ... and Sepsis conditions present in similar ways and require time-critical intervention to avoid large ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, ... choose to buy during the Black Friday and Cyber Monday massage chair sales ... search the Internet high and low to find the best massage chair deals, they ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
Breaking Medicine News(10 mins):